He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
Replicate will receive research funding and could potentially receive up to approximately US$550 million
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Subscribe To Our Newsletter & Stay Updated
